✦ LIBER ✦

Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor

✍ Scribed by Hayashi, Hidetoshi; Kurata, Takayasu; Fujisaka, Yasuhito; Kawakami, Hisato; Tanaka, Kaoru; Okabe, Takafumi; Takeda, Masayuki; Satoh, Taroh; Yoshida, Koji; Tsunoda, Takuya; Arao, Tokuzo; Nishio, Kazuto; Nakagawa, Kazuhiko

Book ID: 119827180
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 193 KB
Volume: 104
Category: Article
ISSN: 1347-9032
DOI: 10.1111/cas.12034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical phase I study of elpamotide, a

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

✍ Okamoto, Isamu; Arao, Tokuzo; Miyazaki, Masaki; Satoh, Taroh; Okamoto, Kunio; Ts 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

Lethality in an anti-angiogenic tumor ge

Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1

✍ Vijayshankar Ganesh Sivanandam; Sam Laurel Stephen; Ruben Hernandez-Alcoceba; Pi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract ## Background Neoangiogenesis is essential for tumor growth. The present study aimed to test the hypothesis that vector‐mediated expression of sflt1 at high levels would result in the blockade of vascular endothelial growth factor (VEGF) function and therefore the inhibition of tumor g

198 POSTER Multi-targeted inhibition of

198 POSTER Multi-targeted inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: a phase I study of cetuxiamb (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors

✍ C. Lin; G. Preston; E. Calvo; K. Papadopoulos; A. Patnaik; J. Sarantopoulos; P. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 60 KB

90 POSTER Inhibition of VEGF (vascular e

90 POSTER Inhibition of VEGF (vascular endothelial growth factor)/VEGF receptor system activation and in vivo tumor-induced angiogenesis by an anti-angiogenic small molecule epoxyquinol B

✍ H. Kamiyama; H. Kakeya; H. Osada 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB

137 A phase I study of an oral vascular

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

✍ Tolcher, A.; O'Leary, J.J.; DeBono, J.; Molpus, K.; Woodard, C.; Warnat, M.; Lia 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

35 POSTER A Phase I trial of a combinati

35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors

✍ G. Dy; G. Croghan; A. Furth; J. Reid; L. Hanson; M. Roos; A. Tan; A. Adjei 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 134 KB